Is Apellis Pharmaceuticals Inc (APLS) overvalued? · rev $781.4M
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
This page asks whether Apellis Pharmaceuticals Inc (APLS) looks expensive on cached numbers — not a short thesis.
Latest reported APLS revenue for 2024-12-31 was $781.4M. Net income was -$197.9M. Revenue was up 97.0% from 2023-12-31 to 2024-12-31. APLS currently screens at market cap $2.29B.
APLS currently screens at market cap $2.29B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next APLS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the APLS stock page for the full model, not this heading.
Not investment advice.